Expression of p53 protein and Ki-67 antigen in gingival hyperplasia induced by nifedipine and phenytoin

Journal of Periodontology

Volumn 70, Issue 6, 1999, Pages 581-586

  Saito, Keiichi ^a   Mori, Shiro ^b   Tanda, Naoko ^a   Sakamoto, Seizaburo ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b NONE

Author keywords

Carcinoma; Cyclosporin A adverse effects; Gingival hyperplasia complications; Phenytoin adverse effects; Squamous cell physiopathology

Indexed keywords

CYCLOSPORIN A; DNA; KI 67 ANTIGEN; NIFEDIPINE; PHENYTOIN; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG INDUCED DISEASE; FEMALE; GINGIVA HYPERPLASIA; HUMAN; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; CULTURE TECHNIQUES; DNA DAMAGE; FEMALE; FIBROBLASTS; GINGIVAL HYPERPLASIA; GINGIVAL NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NIFEDIPINE; PHENYTOIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033021646     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.1999.70.6.581     Document Type: Article

References (47)

1. Donehower LA. Effects of p53 mutation on tumor progression: Recent insights from mouse tumor models. Biochem Biophys Acta 1996;1242:171-176.
2. Gottlieb TM, Oren M. p53 in growth control and neoplasia. BBA 1996;1287:77-102.
3. Kastan MB, Onyekwere O, Sindransky D, Vogelstein B, Crang RW. Participation of p53 protein in cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
4. Finlay CA, Hinds PW, Tan TH, Eliyaku D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc 70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-539.
5. Zambetti GP, Levine AJ. A comparison of biological activities of wild-type and mutant p53. FASEB J 1993;7:855-865.
6. Gerdes J, Lemke M, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
7. Zoeller J, Flentje M, Sinn P, Born IA. Evaluation of AgNOR and Ki-67 antigen as cell kinetic parameters in oral dysplasia and carcinomas. Anal Cell Pathol 1994;7:77-88.
8. Saito K, Mori S, Iwakura M, Sakamoto S. Immunohistochemical localization of transforming growth factor ß, basic fibroblast growth factor and heparan sulphate glycosaminoglycan in gingival hyperplasia induced by nifedipine and phenytoin. J Periodont Res 1996;31:545-555.
9. James JA, Irwin CR, Linden GJ. Gingival fibroblast response to cyclosporin A and transforming growth factor-ß1. J Periodont Res 1998;3:40-48.
10. Kai T, Taketazu F, Kawakami M, et al. Distribution of transforming growth factor-ß and receptors in gastric carcinoma tissue. Jpn J Cancer Res 1996;87:296-304.
11. Myoken Y, Myoken Y, Okamoto T, et al. Immunohistochemical study of overexpression of fibroblast growth factor-1 (FGF1), FGF-2, and FGF receptor-1 in human malignant salivary gland tumours. J Pathol 1996;178:429-436.
12. Kenow J, Wiedemann G. Transforming growth factor ß: A cytokine with multiple actions in oncology and potential clinical applications. Int J Oncol 1995;7:177-182.
13. Wright JA, Hung A. Growth factors in mechanisms of malignancy: Roles for TGF-ß and FGF. Histol Histopathol 1996;11:521-536.
14. Sherman JH, Miller ML, Albert RE, Baxter CS. Dose- and time-dependent expression of transforming growth factor-ß1 mRNA and protein in mouse epidermis and papillomas after repeated topical application of benzo[a]pyrene. Mol Carcinog 1993;8:264-271.
15. Patamalai B, Burow DL, Gimenez-Conti I, et al. Altered expression of transforming growth factor-ß1 mRNA and protein in mouse skin carcinogenesis. Mol Carcinog 1994;9:220-229.
16. Zenklusen JC, Stockman SL, Fischer SM, Conti CJ, Gimenez-Conti IB. Transforming growth factor-ß1 expression in Syrian hamster cheek pouch carcinogenesis. Mol. Carcinog 1994;9:10-16.
17. Varga E, Tyldesley WR. Carcinoma arising cyclosporin-induced gingival hyperplasia. Br Dent J 1991;171:26-27.
18. McLoughlin P, Newman L, Brown A. Oral squamous cell carcinoma arising in phenytoin-induced hyperplasia. Br Dent J 1995;178:183-184.
19. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493-497.
20. Olsen JH, Schulgen G, Boice JD, Whysner J, Travis LB, Williams GH. Anti-epileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. Cancer Res 1995;55:294-297.
21. Bavinck JNB, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. Transplantation 1996;61:715-721.
22. Kusama K, Okutsu S, Takeda A, et al. p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. J Pathol 1996;178:415-421.
23. Kaur J, Srivastava A, Ralhan R. Overexpression of p53 protein in betel- and tobacco-related human oral dysplasia and squamous cell carcinoma in India. Int J Cancer 1994;58:340-345.
24. Kuttan NAA, Rosin MP, Ambika K, Priddy RW, Bhakthan NMG, Zhang L. High prevalence of expression of p53 oncoprotein in oral carcinomas from India associated with betel and tobacco chewing. Oral Oncol Eur J Cancer 1995;31:169-173.
25. Charpin C, DeVictor B, Andrac L, et al. p53 quantitative immunocytochemical analysis in breast carcinoma. Hum Pathol 1995;26:159-166.
26. Müler W, Borchard F. Prognostic influence of p53 expression in gastric cancer. J Pathol 1996;178:255-258
27. Zariwala M, Schmid S, Pfaltz M, Ohgaki H, Kleihues P, Schafer R. p53 gene mutations in oropharyngeal carcinomas: A comparison of solitary and multiple primary tumours and lymph-node metastasis. Int J Cancer 1994;56:807-811.
28. El-Naggar AK, Lai S, Luna MA, et al. Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. Int J Cancer 1995;64:196-201.
29. Shin DM, Kim J, Ro JY, Roth JA, Hong WK, Hittelman WN. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:321-326.
30. Nakanishi Y, Noguchi M, Matsuno Y, et al. p53 expression in multicentric squamous cell carcinoma and surrounding squamous epithelium of the upper aerodigestive tract. Cancer 1995;75:1657-1662.
31. Piffkó J, Bankfalvl A, Öner D, et al. Expression of p53 protein in oral squamous cell carcinomas and adjacent non-tumorous mucosa of the mouse: An archival immunohistochemical study using wet autoclave pretreatment for antigen retrieval. J Oral Pathol Med 1995;24:337-342.
32. Bártek J, Bártkova J, Vojtesek B, et al. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer 1990;46:839-844.
33. Urano Y, Asano T, Yoshimoto K, et al. Frequent p53 accumulation in the chronically sun-exposed epidermis and clonal expression of p53 mutant cells in the epidermis adjacent to basal cell carcinoma. J Invest Dermatol 1995;104:928-932.
34. Pruneri G, Pignataro L, Fracchiolla NS, et al. p53 protein expression in laryngeal squamous cell carcinomas bearing wild-type and mutated p53 gene. Histopathol 1996;28:513-519.
35. Nees M, Homann N, Discher H, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: A possible molecular basis for the development of multiple tumors. Cancer Res 1993;53:4189-4196.
36. Campbell C, Quinn AG, Angus B, Farr PM, Rees JL. Wavelength specific patterns of p53 induction in human skin following exposure to UV radiation. Cancer Res 1993;53:2697-2699.
37. Hall PA, McKee PH, Menage HP, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993;8:203-207.
38. Berg RJW, van Kranen HJ, Rebel HG, et al. Early p53 alterations in mouse skin carcinogenesis by UVB radiation: Immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. Proc Natl Acad Svi (USA) 1996;93:274-278.
39. Nakazawa H, English D, Randell PL, et al. UV and skin cancer: Specific p53 gene mutation in normal skin as a biological relevant exposure measurement. Proc Natl Acad Sci (USA) 1994;91:360-364.
40. Bjelogrlic NM, Makinen M, Stenback F, Vahakangas K. Benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts and increased p53 protein in mouse skin. Carcinogenesis 1994;15:771-774.
41. Hubbs AF, Hahn F, Thomassen DG. Increased resistance to transforming growth factor beta accompanies neoplastic progression of tracheal epithelial cells. Carcinogenesis 1989;10:1599-1605.
42. Jacobberger JW, Sizemore N, Gorodeski G, Rorke EA. Transforming growth factor ß regulation of epidermal growth factor receptor in ectocervical epithelial cells. Exp Cell Res 1995;220:390-396.
43. Appleton I, Brown NJ, Willoughby DA. Apoptosis, necrosis, and proliferation: Possible implication in the etiology of keloids. Am J Pathol 1996;149:1441-1447.
44. Iacopino AM, Doxey D, Cutler CW, et al. Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: Possible molecular mechanism of drug-induced gingival hyperplasia. J Periodontol 1997;68:73-83.
45. Dennison DK, Vallone DR, Pinero GJ, Rittman B, Caffesse RG. Differential effect of TGF-ß1 and PDGF on proliferation of periodontal ligament cells and gingival fibroblasts. J Periodontol 1994;65:641-648.
46. Clark RAF, McCoy GA, Folkvord JM, McPherson JM. TGF-ß1 stimulates cultured human fibroblasts to proliferate and produce tissue-like fibroplasia: A fibronectin matrix-dependent event. J Cell Physiol 1997;170:69-80.
47. Kay EP, Lee MS, Seong GJ, Lee YG. TGF-ßs stimulate cell proliferation via an autocrine production of FGF-2 in corneal stromal fibroblasts. Curr Eye Res 1998;17:286-293.